Galectin Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Galectin Therapeutics has a total shareholder equity of $-60.2M and total debt of $71.7M, which brings its debt-to-equity ratio to -119.1%. Its total assets and total liabilities are $28.2M and $88.4M respectively.
Key information
-119.1%
Debt to equity ratio
US$71.74m
Debt
Interest coverage ratio | n/a |
Cash | US$25.66m |
Equity | -US$60.24m |
Total liabilities | US$88.44m |
Total assets | US$28.20m |
Recent financial health updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Financial Position Analysis
Short Term Liabilities: GALT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: GALT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: GALT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: GALT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GALT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GALT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.8% each year